ObesityManagement

Novo Nordisk Suffers Leadership Shake-Up as 28-Year Veteran Executive Departs

17 days ago

Novo Nordisk, a global leader in diabetes and obesity care, is facing another significant change in its executive ranks. The company has announced the sudden departure of Thomas Husted, who has been with the organization for nearly three decades. Husted, who most recently held the role of Executive Vice President, is credited with playing a pivotal role in expanding Novo Nordisk's international reach and solidifying its status within the pharmaceutical industry.

Hims Teams Up with Eli Lilly to Offer Zepbound Through Telehealth Services

19 days ago

In a significant development within the telehealth industry, Hims, a leading healthcare company focused on providing convenient access to prescription medications and wellness products, announced that it will begin selling Eli Lilly’s weight-loss drug, Zepbound, through its online platform. This strategic partnership marks a pivotal moment for both companies as they seek to expand their reach in the weight management market.

End of Ozempic and Wegovy Shortages: Novo Nordisk's Strategy Against Competition

2 months ago

In an encouraging turn of events, Novo Nordisk has announced the conclusion of the shortages affecting its prominent diabetes and obesity medications, Ozempic and Wegovy. The pharmaceutical giant's statement indicates a significant scale-up in production, alleviating widespread concerns that had been troubling patients and healthcare providers alike.